Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, AI-powered, incision-free therapies for the ablation of diseased tissue [3]. Key Technologies - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven transurethral ultrasound for prostate disease treatment. The TULSA Procedure is designed to treat various prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [4]. - The TULSA Procedure is characterized as a "one-and-done" treatment performed in a single session, taking a few hours, with no bleeding, no hospital stay required, and quick recovery reported by patients [4]. Regulatory Approvals - TULSA-PRO has received CE marking, Health Canada approval, and 510(k) clearance from the U.S. FDA [4]. - Profound is also commercializing Sonalleve, which is CE marked for treating uterine fibroids and palliative pain from bone metastases, and has received FDA approval under a Humanitarian Device Exemption for treating osteoid osteoma [5]. Future Prospects - The company is exploring additional treatment markets for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy [5]. Upcoming Events - Management will present an update on the company's business at the Stifel 2025 Healthcare Conference on November 11, 2025 [1].